Karen Kabat Stegman

Title: Karen Kabat Stegman: Innovator in Cell Therapy

Introduction

Karen Kabat Stegman is a prominent inventor based in Encinitas, CA (US). She has made significant contributions to the field of cell therapy, particularly through her innovative work on artificial antigen presenting cells. With a total of 2 patents, her research has the potential to advance therapeutic techniques in immunology.

Latest Patents

Karen's latest patents focus on the preparation of inactivated artificial antigen presenting cells (aAPCs) and their application in cell therapies. These patents describe methods for processing aAPCs that are specific for selected antigenic peptides. The generation and use of these cells in compositions comprising activated cytotoxic T lymphocytes are crucial for developing effective cell therapies. Notably, inactivated aAPCs are generated through crosslinking, utilizing a photoreaction involving a psoralen derivative and UVA irradiation.

Career Highlights

Karen Kabat Stegman is currently associated with Janssen Pharmaceutica NV, where she continues to push the boundaries of research in cell therapy. Her work is characterized by a commitment to innovation and excellence in the field of immunotherapy.

Collaborations

Throughout her career, Karen has collaborated with esteemed colleagues, including Zeling Cai and Ann M Moriarty. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic strategies.

Conclusion

Karen Kabat Stegman is a trailblazer in the field of cell therapy, with her innovative patents paving the way for advancements in immunological treatments. Her contributions are invaluable to the scientific community and hold promise for future therapeutic applications.